{"nctId":"NCT00395343","briefTitle":"Sitagliptin Added-on to Insulin Study (0431-051)","startDateStruct":{"date":"2006-12-11","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":641,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin phosphate"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator : placebo (unspecified)"]}],"interventions":[{"name":"sitagliptin phosphate","otherNames":["MK0431","Januviaâ„¢"]},{"name":"Comparator : placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is poorly controlled while on insulin or insulin and metformin\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient is taking oral antidiabetic agents other than metformin during the past 3 months\n* Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 24","description":"A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":null},{"groupId":"OG001","value":"-0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.5","spread":null},{"groupId":"OG001","value":"-3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.9","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Index of Static Beta-Cell Sensitivity to Glucose at Week 24","description":"Static sensitivity is a measure of the effect of glucose on beta-cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. (See Breda and Cobelli, Annals of Biomedical Engineering 29, 692-700 (2001) for more details.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"-8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With A1C < 7.0% at Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With A1C < 6.5% at Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in A1C at Week 24","description":"A1C in subset of patients on long-acting or intermediate-acting insulin.\n\nA1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":null},{"groupId":"OG001","value":"-0.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":322},"commonTop":["Any Metabolism and nutrition disorders","Hypoglycaemia"]}}}